# Effect of Add-on L-Arginine Therapy on Heart Failure Patients

Study · id `cardio:ct-nct07394270` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07394270](<https://clinicaltrials.gov/study/NCT07394270>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT07394270

Browse, organ or system: Heart  
Browse, condition area: Heart failure  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 200 participants.

## Technical summary

Registry record NCT07394270. Randomized; quadruple masking; primary purpose treatment. Start 2026-02 (anticipated); primary completion 2027-03 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 200 participants (planned count; ClinicalTrials.gov record NCT07394270, source copy `cardio:ctgov-nct07394270-2026-02-06`, retrieved 2026-10-26)
- Planned start: 2026-02 (anticipated) (ClinicalTrials.gov record NCT07394270, source copy `cardio:ctgov-nct07394270-2026-02-06`, retrieved 2026-10-26)
- Primary completion: 2027-03 (anticipated) (ClinicalTrials.gov record NCT07394270, source copy `cardio:ctgov-nct07394270-2026-02-06`, retrieved 2026-10-26)
- Completion: 2027-07 (anticipated) (ClinicalTrials.gov record NCT07394270, source copy `cardio:ctgov-nct07394270-2026-02-06`, retrieved 2026-10-26)
- Countries: Egypt (ClinicalTrials.gov record NCT07394270, source copy `cardio:ctgov-nct07394270-2026-02-06`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "NOT\_YET\_RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07394270-2026-02-06`, retrieved 2026-10-26)

## The registry's words

- Brief title: Effect of Add-on L-Arginine Therapy on Heart Failure Patients
- Condition: Heart Failure
- Intervention (Drug): L-Arginine Powder
- Intervention (Drug): Placebo
- Lead sponsor: German University in Cairo
- Lead sponsor class: OTHER
- Collaborator: Ain Shams University
- Collaborator class: OTHER

## Connected pages

- Registry condition terms include this condition: Heart failure (`cardio:heart-failure`)
- Registry lists this organization as a collaborator: Ain Shams University (`cardio:org-ain-shams-university`)

## Provenance

Content hash: 27cee607cc54abb9d624d33e78a4dcbb3ac6cc867e41227eb9fb71bb52185041
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
